Work

A phase III open randomized study of Zoladex 3.6 mg depot vs. DES 3 mg per day in untreated advanced prostate cancer: a West Midlands Urological Research Group Study.

Year: 1989

Type: article

Source: PubMed

Authors: L A Emtage, C Trethowan, K Kelly, D Arkell, D M Wallace, M Hughes, A Hay, R Blacklock, M Jones, A Rouse

Institution: Queen Elizabeth Hospital Birmingham

Language: English

Topic: Prostate Cancer Treatment and Research

Subfield: Cancer Research

Field: Biochemistry, Genetics and Molecular Biology

Domain: Life Sciences

SDG: Good health and well-being

Open Access status: closed

OpenAlex ID: W2411680758

FWCI: 0.205

Cites:

Cited by: 7

Related to: 10